Trump's Drug Pricing Order: Pharma's Survival Strategy with Patient Access Automation
Trump's Drug Pricing Order: Pharma's Survival Strategy with Patient Access Automation
Join us in revolutionizing healthcare administration. Explore how Neon’s AI solutions can help your organization overcome the administrative burden and unlock the full potential of your healthcare team. Contact us today to learn more.
Join us in revolutionizing healthcare administration. Explore how Neon’s AI solutions can help your organization overcome the administrative burden and unlock the full potential of your healthcare team. Contact us today to learn more.
The recent executive order on drug pricing issued by the Trump administration poses significant challenges for the pharmaceutical industry, potentially reshaping market dynamics and threatening traditional revenue models. By aiming to lower prescription drug costs, particularly for Medicare beneficiaries, the order introduces new pressures on pricing strategies, reimbursement processes, and patient access frameworks. For pharmaceutical companies, adapting to these changes is critical to maintaining competitiveness and avoiding severe financial repercussions.
The recent executive order on drug pricing issued by the Trump administration poses significant challenges for the pharmaceutical industry, potentially reshaping market dynamics and threatening traditional revenue models. By aiming to lower prescription drug costs, particularly for Medicare beneficiaries, the order introduces new pressures on pricing strategies, reimbursement processes, and patient access frameworks. For pharmaceutical companies, adapting to these changes is critical to maintaining competitiveness and avoiding severe financial repercussions.
Patient Access Automation as a Survival Strategy
To address the complexities introduced by the executive order, pharmaceutical companies must prioritize automation and streamlined processes in their patient access operations. The following areas highlight where strategic investments can mitigate risks and position companies for long-term success.
Benefit Verifications & Prior Auths
Manual processes = dead weight. Digitize intake, and build real-time payer connectivity—or fall behind. New complexities (e.g., provider reimbursement, Medicare policy changes) will demand smarter support.
Payer Formulary Monitoring
Drugs once blocked due to high cost may gain preferred tier status. But PBMs won’t go quietly—expect new controls elsewhere — and formulary volatility. Build dashboards that track real-time PBM shifts to guide access strategy.
Training & Policy Rollouts
When CMS guidance changes weekly, static SOPs won’t cut it. Automate microlearning and push updates directly to field teams.
Affordability Programs Will Get Leaner
Less need for copay aid in Medicare, but more focus on education, adherence, and targeted support for uninsured/underinsured patients.
Access Roles Are Evolving
Think: fewer rote tasks, more field education, real-time payer tracking, and tight alignment with policy, pricing, and data teams.
Silver Lining: More Patients on Therapy
Cheaper drugs could mean higher volume, better adherence, and (if access is done right) a net win for patients and revenue.
2025 is a reset year
Access teams must adapt fast—streamline and automate their critical operations, stay close to payers, and prove value beyond "getting drugs covered."
To address the complexities introduced by the executive order, pharmaceutical companies must prioritize automation and streamlined processes in their patient access operations. The following areas highlight where strategic investments can mitigate risks and position companies for long-term success.
Benefit Verifications & Prior Auths
Manual processes = dead weight. Digitize intake, and build real-time payer connectivity—or fall behind. New complexities (e.g., provider reimbursement, Medicare policy changes) will demand smarter support.
Payer Formulary Monitoring
Drugs once blocked due to high cost may gain preferred tier status. But PBMs won’t go quietly—expect new controls elsewhere — and formulary volatility. Build dashboards that track real-time PBM shifts to guide access strategy.
Training & Policy Rollouts
When CMS guidance changes weekly, static SOPs won’t cut it. Automate microlearning and push updates directly to field teams.
Affordability Programs Will Get Leaner
Less need for copay aid in Medicare, but more focus on education, adherence, and targeted support for uninsured/underinsured patients.
Access Roles Are Evolving
Think: fewer rote tasks, more field education, real-time payer tracking, and tight alignment with policy, pricing, and data teams.
Silver Lining: More Patients on Therapy
Cheaper drugs could mean higher volume, better adherence, and (if access is done right) a net win for patients and revenue.
2025 is a reset year
Access teams must adapt fast—streamline and automate their critical operations, stay close to payers, and prove value beyond "getting drugs covered."
Aim to Adapt
The Trump administration’s drug pricing executive order represents a transformative challenge for the pharmaceutical industry, with far-reaching implications for pricing, access, and operational strategies. While the order introduces significant risks, it also creates opportunities for companies to rethink their approach to patient access and market competitiveness. By embracing automation, enhancing payer engagement, and prioritizing patient-centric solutions, pharmaceutical companies can navigate this complex environment and position themselves for success in 2025 and beyond. The path forward requires strategic investment, adaptability, and a commitment to delivering value to patients and stakeholders alike.
The Trump administration’s drug pricing executive order represents a transformative challenge for the pharmaceutical industry, with far-reaching implications for pricing, access, and operational strategies. While the order introduces significant risks, it also creates opportunities for companies to rethink their approach to patient access and market competitiveness. By embracing automation, enhancing payer engagement, and prioritizing patient-centric solutions, pharmaceutical companies can navigate this complex environment and position themselves for success in 2025 and beyond. The path forward requires strategic investment, adaptability, and a commitment to delivering value to patients and stakeholders alike.
Related articles
Related articles
Ready to transform Patient Access?
Ready to transform Patient Access?
Experience firsthand how Neon can streamline your patient access operations and dramatically enhance your bottom line.
Experience firsthand how Neon can streamline your patient access operations and dramatically enhance your bottom line.